OTTAWA: Canada has struck deals in place with pharmaceutical giant Pfizer and U.S.-based biotech firm Moderna to secure millions of doses of their experimental COVID-19 vaccines, in case either of the candidates is approved for wide-scale use.
Pharmaceutical giant Pfizer will supply its BNT162 mRNA-based vaccine candidate, while Moderna will provide its mRNA-1273 vaccine candidate.
Even though the details of the agreements reached with Moderna and Pfizer Inc., including the cost of the vaccines, have not been disclosed, but Public Service and Procurement Canada Minister Anita Anand said that millions of doses have been ordered from the two companies for delivery in 2021.
“We are working on all possible fronts and diversifying our vaccine supply chain,” Anand said.
“These vaccine candidates are very promising and we all look forward to the day when restrictions can be lifted entirely,” Anand during a news conference in Toronto.
Last month, Pfizer inked a deal with the U.S. government to supply the first 100 million doses of the vaccine it is developing in December.
The vaccine developed by Moderna, a Massachusetts-based biotech company, yielded promising results in an early study published last month in the New England Journal of Medicine.